STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests

Contributed by: Business Wire

Logo

Images

STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit is now classified by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment. (Photo: Business Wire)

Business Wire embedded0

Tags

Oncology

Health

FDA

Medical Devices

Clinical Trials

Pharmaceutical

Biotechnology

STEMCELL Technologies

More Like This

PR Newswire associated0

Menarini Silicon Biosystems announces publication of the DETECT III trial results highlighting the potential clinical utility of HER2 testing in circulating tumor cells with CELLSEARCH

CleanNA Enters the Molecular Diagnostics Market by Launching Its First CE-IVD Product

PK MED Receives €1.5M DeepTech Non-Dilutive Financing From Bpifrance for the Development of a Local Cell-Homing Implant to Enhance Bone Marrow Transplantation

PR Newswire associated0

Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients

PR Newswire associated0

/C O R R E C T I O N -- Menarini Silicon Biosystems/

PR Newswire associated0

CELLSEARCH® CTC count proves its clinical utility in guiding therapeutic strategy supporting patient care in HR+/HER2- metastatic breast cancer

PR Newswire associated0

Menarini Silicon Biosystems announces new study results on use of CELLSEARCH® liquid biopsy for earlier detection of relapse and to help inform decisions on patient management in stage III Melanoma

EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA